Drug-mediated ototoxicity and tinnitus

Alleviation with melatonin

Russel J Reiter, D. X. Tan, A. Korkmaz, L. Fuentes-Broto

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

This review evaluates the published basic science and clinical reports related to the role of melatonin in reducing the side effects of aminoglycosides and the cancer chemotherapeutic agent cisplatin, in the cochlea and vestibule of the inner ear. A thorough search of the literature was performed using available databases for the purpose of uncovering articles applicable to the current review. Cochlear function was most frequently evaluated by measuring otoacoustic emissions and their distortion products after animals were treated with cytotoxic drugs alone or in combination with melatonin. Vestibular damage due to aminoglycosides was evaluated by estimating hair cell loss in explanted utricles of newborn rats. Tinnitus was assessed in patients who received melatonin using a visual analogue scale or the Tinnitus Handicap Inventory. Compared to a mixture of antioxidants which included tocopherol, ascorbate, glutathione and N-acetylcysteine, melatonin, also a documented antioxidant, was estimated to be up to 150 times more effective in limiting the cochlear side effects, evaluated using otoacoustic emission distortion products, of gentamicin, tobramycin and cisplatin. In a dose-response manner, melatonin also reduced vestibular hair cell loss due to gentamicin treatment in explanted utricles of newborn rats. Finally, melatonin (3 mg daily) limited subjective tinnitus in patients. These findings suggest the potential use of melatonin to combat the ototoxicity of aminoglycosides and cancer chemotherapeutic agents. Additional studies at both the experimental and clinical levels should be performed to further document the actions of melatonin at the cochlear and vestibular levels to further clarify the protective mechanisms of action of this ubiquitouslyacting molecule. Melatonin's low cost and minimal toxicity profile supports its use to protect the inner ear from drugmediated damage.

Original languageEnglish (US)
Pages (from-to)151-157
Number of pages7
JournalJournal of Physiology and Pharmacology
Volume62
Issue number2
StatePublished - Apr 2011

Fingerprint

Tinnitus
Melatonin
Cochlea
Pharmaceutical Preparations
Aminoglycosides
Saccule and Utricle
Alopecia
Inner Ear
Gentamicins
Cisplatin
Antioxidants
Vestibular Hair Cells
Labyrinth Vestibule
Tobramycin
Tocopherols
Acetylcysteine
Visual Analog Scale
Glutathione
Neoplasms
Databases

Keywords

  • Antioxidant
  • Cochlea
  • Free radicals
  • Melatonin
  • Ototoxicity
  • Tinnitus
  • Vestibular system

ASJC Scopus subject areas

  • Pharmacology
  • Physiology

Cite this

Drug-mediated ototoxicity and tinnitus : Alleviation with melatonin. / Reiter, Russel J; Tan, D. X.; Korkmaz, A.; Fuentes-Broto, L.

In: Journal of Physiology and Pharmacology, Vol. 62, No. 2, 04.2011, p. 151-157.

Research output: Contribution to journalArticle

Reiter, RJ, Tan, DX, Korkmaz, A & Fuentes-Broto, L 2011, 'Drug-mediated ototoxicity and tinnitus: Alleviation with melatonin', Journal of Physiology and Pharmacology, vol. 62, no. 2, pp. 151-157.
Reiter, Russel J ; Tan, D. X. ; Korkmaz, A. ; Fuentes-Broto, L. / Drug-mediated ototoxicity and tinnitus : Alleviation with melatonin. In: Journal of Physiology and Pharmacology. 2011 ; Vol. 62, No. 2. pp. 151-157.
@article{9498d2d24e3145a6b9ea9a84256389c9,
title = "Drug-mediated ototoxicity and tinnitus: Alleviation with melatonin",
abstract = "This review evaluates the published basic science and clinical reports related to the role of melatonin in reducing the side effects of aminoglycosides and the cancer chemotherapeutic agent cisplatin, in the cochlea and vestibule of the inner ear. A thorough search of the literature was performed using available databases for the purpose of uncovering articles applicable to the current review. Cochlear function was most frequently evaluated by measuring otoacoustic emissions and their distortion products after animals were treated with cytotoxic drugs alone or in combination with melatonin. Vestibular damage due to aminoglycosides was evaluated by estimating hair cell loss in explanted utricles of newborn rats. Tinnitus was assessed in patients who received melatonin using a visual analogue scale or the Tinnitus Handicap Inventory. Compared to a mixture of antioxidants which included tocopherol, ascorbate, glutathione and N-acetylcysteine, melatonin, also a documented antioxidant, was estimated to be up to 150 times more effective in limiting the cochlear side effects, evaluated using otoacoustic emission distortion products, of gentamicin, tobramycin and cisplatin. In a dose-response manner, melatonin also reduced vestibular hair cell loss due to gentamicin treatment in explanted utricles of newborn rats. Finally, melatonin (3 mg daily) limited subjective tinnitus in patients. These findings suggest the potential use of melatonin to combat the ototoxicity of aminoglycosides and cancer chemotherapeutic agents. Additional studies at both the experimental and clinical levels should be performed to further document the actions of melatonin at the cochlear and vestibular levels to further clarify the protective mechanisms of action of this ubiquitouslyacting molecule. Melatonin's low cost and minimal toxicity profile supports its use to protect the inner ear from drugmediated damage.",
keywords = "Antioxidant, Cochlea, Free radicals, Melatonin, Ototoxicity, Tinnitus, Vestibular system",
author = "Reiter, {Russel J} and Tan, {D. X.} and A. Korkmaz and L. Fuentes-Broto",
year = "2011",
month = "4",
language = "English (US)",
volume = "62",
pages = "151--157",
journal = "Journal of Physiology and Pharmacology",
issn = "0867-5910",
publisher = "Polish Physiological Society",
number = "2",

}

TY - JOUR

T1 - Drug-mediated ototoxicity and tinnitus

T2 - Alleviation with melatonin

AU - Reiter, Russel J

AU - Tan, D. X.

AU - Korkmaz, A.

AU - Fuentes-Broto, L.

PY - 2011/4

Y1 - 2011/4

N2 - This review evaluates the published basic science and clinical reports related to the role of melatonin in reducing the side effects of aminoglycosides and the cancer chemotherapeutic agent cisplatin, in the cochlea and vestibule of the inner ear. A thorough search of the literature was performed using available databases for the purpose of uncovering articles applicable to the current review. Cochlear function was most frequently evaluated by measuring otoacoustic emissions and their distortion products after animals were treated with cytotoxic drugs alone or in combination with melatonin. Vestibular damage due to aminoglycosides was evaluated by estimating hair cell loss in explanted utricles of newborn rats. Tinnitus was assessed in patients who received melatonin using a visual analogue scale or the Tinnitus Handicap Inventory. Compared to a mixture of antioxidants which included tocopherol, ascorbate, glutathione and N-acetylcysteine, melatonin, also a documented antioxidant, was estimated to be up to 150 times more effective in limiting the cochlear side effects, evaluated using otoacoustic emission distortion products, of gentamicin, tobramycin and cisplatin. In a dose-response manner, melatonin also reduced vestibular hair cell loss due to gentamicin treatment in explanted utricles of newborn rats. Finally, melatonin (3 mg daily) limited subjective tinnitus in patients. These findings suggest the potential use of melatonin to combat the ototoxicity of aminoglycosides and cancer chemotherapeutic agents. Additional studies at both the experimental and clinical levels should be performed to further document the actions of melatonin at the cochlear and vestibular levels to further clarify the protective mechanisms of action of this ubiquitouslyacting molecule. Melatonin's low cost and minimal toxicity profile supports its use to protect the inner ear from drugmediated damage.

AB - This review evaluates the published basic science and clinical reports related to the role of melatonin in reducing the side effects of aminoglycosides and the cancer chemotherapeutic agent cisplatin, in the cochlea and vestibule of the inner ear. A thorough search of the literature was performed using available databases for the purpose of uncovering articles applicable to the current review. Cochlear function was most frequently evaluated by measuring otoacoustic emissions and their distortion products after animals were treated with cytotoxic drugs alone or in combination with melatonin. Vestibular damage due to aminoglycosides was evaluated by estimating hair cell loss in explanted utricles of newborn rats. Tinnitus was assessed in patients who received melatonin using a visual analogue scale or the Tinnitus Handicap Inventory. Compared to a mixture of antioxidants which included tocopherol, ascorbate, glutathione and N-acetylcysteine, melatonin, also a documented antioxidant, was estimated to be up to 150 times more effective in limiting the cochlear side effects, evaluated using otoacoustic emission distortion products, of gentamicin, tobramycin and cisplatin. In a dose-response manner, melatonin also reduced vestibular hair cell loss due to gentamicin treatment in explanted utricles of newborn rats. Finally, melatonin (3 mg daily) limited subjective tinnitus in patients. These findings suggest the potential use of melatonin to combat the ototoxicity of aminoglycosides and cancer chemotherapeutic agents. Additional studies at both the experimental and clinical levels should be performed to further document the actions of melatonin at the cochlear and vestibular levels to further clarify the protective mechanisms of action of this ubiquitouslyacting molecule. Melatonin's low cost and minimal toxicity profile supports its use to protect the inner ear from drugmediated damage.

KW - Antioxidant

KW - Cochlea

KW - Free radicals

KW - Melatonin

KW - Ototoxicity

KW - Tinnitus

KW - Vestibular system

UR - http://www.scopus.com/inward/record.url?scp=79959342434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959342434&partnerID=8YFLogxK

M3 - Article

VL - 62

SP - 151

EP - 157

JO - Journal of Physiology and Pharmacology

JF - Journal of Physiology and Pharmacology

SN - 0867-5910

IS - 2

ER -